Intravesical application of Gemicitabine for superficial bladder cancer resistant to intrvesical immunotherapy with BCG vaccine
| Autor: | I. V. Seregin, V. M. Samoylenko, K. M. Figurin |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Onkourologiâ, Vol 1, Iss 2, Pp 32-34 (2020) |
| ISSN: | 1996-1812 1726-9776 |
| Popis: | Transurethral removal of tumor with following intravesical chemotherapy with Gemicitabine were performed to 14 patients with superficial bladder cancer relapses after TUR with adjuvant intravesical BCG – therapy. Adjuvant treatment was initiated 2 – 3 weeks after TUR: 1000 mg of gemicitabine was solved in 100 ml of physiologic solution and instillated into the bladder 2 times a week for 3 week. After 1 week break the second course of chemotherapy was carried out.Treatment was well tolerated by all patients. The follow-up period ranged from 1,5 to 22 months (mean 10,6±7,0 months). After mean period of 11,3 months 10 patients were disease free. Recurrence developed in 4 patients with multifocal bladder relapses. No disease progression was registered. Adjuvand intravesical chemotherapy with Gemicitabine is effective in patients with recurrences of superficial bladder cancer and is well tolerated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|